American College of Cardiology conference organizers cancel the highly anticipated presentation of preliminary results from Boston Scientific’s PREVAIL study after the company leaks the data ahead of time. Boston Scientific publishes the slides that would have been presented at this weekend’s American College of Cardiology meeting had the company preserved the embargo on the findings.
Medical device giant Boston Scientific (NYSE:BSX) did not present its highly anticipated PREVAIL clinical trial results at the American College of Cardiology conference as planned this weekend after the presentation was canceled when the company leaked the data ahead of time.
Boston Scientific leaked a press release to its investors Saturday morning, breaking an embargo on the study that was meant to be lifted during the presentation.
